Literature DB >> 20031906

Vision and creation of the American Heart Association pharmaceutical roundtable outcomes research centers.

Eric D Peterson1, John A Spertus, David J Cohen, Mark A Hlatky, Alan S Go, Barbara G Vickrey, Jeffrey L Saver, Patricia C Hinton.   

Abstract

BACKGROUND: The field of outcomes research seeks to define optimal treatment in practice and to promote the rapid full adoption of efficacious therapies into routine clinical care. The American Heart Association (AHA) formed the AHA Pharmaceutical Roundtable (PRT) Outcomes Research Centers Network to accelerate attainment of these goals. Participating centers were intended to carry out state-of-the-art outcomes research in cardiovascular disease and stroke, to train the next generation of investigators, and to support the formation of a collaborative research network. PROGRAM: After a competitive application process, 4 AHA PRT Outcomes Research Centers were selected: Duke Clinical Research Institute; Saint Luke's Mid America Heart Institute; Stanford University-Kaiser Permanente of Northern California; and University of California, Los Angeles. Each center proposed between 1 and 3 projects organized around a single theme in cardiovascular disease or stroke. Additionally, each center will select and train up to 6 postdoctoral fellows over the next 4 years, and will participate in cross-collaborative activities among the centers.
CONCLUSIONS: The AHA PRT Outcomes Research Centers Network is designed to further strengthen the field of cardiovascular disease and stroke outcomes research by fostering innovative research, supporting high quality training, and encouraging center-to-center collaborations.

Entities:  

Mesh:

Year:  2009        PMID: 20031906      PMCID: PMC4567255          DOI: 10.1161/CIRCOUTCOMES.109.868612

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN: 1941-7713


  44 in total

Review 1.  Designing and evaluating interventions to eliminate racial and ethnic disparities in health care.

Authors:  Lisa A Cooper; Martha N Hill; Neil R Powe
Journal:  J Gen Intern Med       Date:  2002-06       Impact factor: 5.128

Review 2.  Outcomes research: generating evidence for best practice and policies.

Authors:  Harlan M Krumholz
Journal:  Circulation       Date:  2008-07-15       Impact factor: 29.690

3.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

4.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

5.  Neighbourhood environments and mortality in an elderly cohort: results from the cardiovascular health study.

Authors:  Ana V Diez Roux; Luisa N Borrell; Mary Haan; Sharon A Jackson; Richard Schultz
Journal:  J Epidemiol Community Health       Date:  2004-11       Impact factor: 3.710

Review 6.  Multidetector computed tomography for the diagnosis of coronary artery disease: a systematic review.

Authors:  Paul D Stein; Afzal Beemath; Fadi Kayali; Elias Skaf; Julia Sanchez; Ronald E Olson
Journal:  Am J Med       Date:  2006-03       Impact factor: 4.965

7.  The relationship between neighborhood characteristics and self-rated health for adults with chronic conditions.

Authors:  Arleen F Brown; Alfonso Ang; Anne R Pebley
Journal:  Am J Public Health       Date:  2007-03-29       Impact factor: 9.308

8.  Results of coronary artery surgery in patients with poor left ventricular function (CASS).

Authors:  E L Alderman; L D Fisher; P Litwin; G C Kaiser; W O Myers; C Maynard; F Levine; M Schloss
Journal:  Circulation       Date:  1983-10       Impact factor: 29.690

9.  Evaluating medication effects outside of clinical trials: new-user designs.

Authors:  Wayne A Ray
Journal:  Am J Epidemiol       Date:  2003-11-01       Impact factor: 4.897

Review 10.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.

Authors:  Mark J Sarnak; Andrew S Levey; Anton C Schoolwerth; Josef Coresh; Bruce Culleton; L Lee Hamm; Peter A McCullough; Bertram L Kasiske; Ellie Kelepouris; Michael J Klag; Patrick Parfrey; Marc Pfeffer; Leopoldo Raij; David J Spinosa; Peter W Wilson
Journal:  Circulation       Date:  2003-10-28       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.